GLP-1 (7-36)
Glucagon-Like Peptide-1 (7-36) Amide
The native active form of GLP-1, produced by intestinal L-cells. The basis for all GLP-1 receptor agonist drugs. Has a very short half-life of 2 minutes.
Mechanism of Action
GLP-1 (7-36) binds to GLP-1 receptors on pancreatic beta cells, brain, heart, and other tissues. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite.
Health Claims & Evidence
Stimulates insulin secretion in a glucose-dependent manner
Suppresses glucagon and reduces postprandial glucose
Neuroprotective effects
Short-Term Effects
Insulin secretion, glucagon suppression, appetite reduction.
Long-Term Effects
Research use primarily.
Side Effects
Nausea at high doses.
Contraindications
Research use only as native peptide.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
GLP-1 and incretin pharmacology
Holst et al. · Physiological Reviews · 2007
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on GLP-1 (7-36) and related peptides, and prepare an educational research summary.
Explore Research